The new ACC/AHA cardiovascular risk guidelines: impact and controversies

The ATP-III guidelines had specific LDL-C treatment goals, namely LDL-C 100 mg/dL (2.59 mmol/L) for primary prevention and LDL-C70 mg/dL (1.81 mmol/L) for secondary prevention. Since the new guidelines were mostly on the basis of randomized clinical trials that used a fixed statin dose, there is lim...

Full description

Saved in:
Bibliographic Details
Published in:Clinical chemistry (Baltimore, Md.) Md.), 2014-11, Vol.60 (11), p.1365-1367
Main Authors: Remaley, Alan T, Shamburek, Robert D, Amar, Marcelo
Format: Article
Language:English
Subjects:
Cardiovascular Diseases - drug therapy
Cardiovascular Diseases - prevention & control
Cholesterol
Health risk assessment
Heart attacks
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage
Medicine
Practice Guidelines as Topic
Risk Factors
Statins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The ATP-III guidelines had specific LDL-C treatment goals, namely LDL-C 100 mg/dL (2.59 mmol/L) for primary prevention and LDL-C70 mg/dL (1.81 mmol/L) for secondary prevention. Since the new guidelines were mostly on the basis of randomized clinical trials that used a fixed statin dose, there is limited evidence supporting the clinical value of treating toward a LDL-C goal. Because we know that it takes several decades for atherosclerosis to develop and manifest clinically, many would argue that it would be best to treat this patient early on to prevent him from developing atherosclerosis and getting a myocardial infarction before the age of 56 years.
ISSN:0009-9147
1530-8561
DOI:10.1373/clinchem.2014.224964